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Preeclampsia and preterm delivery are important potential complications in pregnancy and represent the leading causes for
maternal and perinatal morbidity and mortality. The mechanisms underlying both diseases remain unknown, thus available
treatments (beta2-stimulants and magnesium sulfate) are essentially symptomatic. Both molecules have molecular weights less
than 5–8kDa, cross the placental barrier, and thus exert their eﬀects on the fetus. The fetus produces peptides that are highly
vasoactiveanduterotonicandincreaseinresponsetomaternalstressandwithcontinueddevelopment.Fetalpeptidesarealsosmall
molecules that inevitably leak across into the maternal circulation. Aminopeptidases such as placental leucine aminopeptidase (P-
LAP) and aminopeptidase A (APA) are large molecules that do not cross the placental barrier. We have shown that APA acts
as an antihypertensive agent in the pregnant spontaneously hypertensive rat by degrading vasoactive peptides and as a result
returns the animal to a normotensive state. P-LAP also acts as an antiuterotonic agent by degrading uterotonic peptides and thus
prolongs gestation in the pregnant mouse. Given the ever increasing worldwide incidences of preeclampsia and preterm labor, it is
imperative that new agents be developed to safely prolong gestation. We believe that the use of aminopeptidases hold promise in
this regard.
1.Introduction
It is well known that the fetus produces bioactive peptides
such as angiotensin II (AngII), vasopressin (AVP), and
oxytocin (OT), that are highly vasoactive and uterotonic,
respectively [1–4]. It is also known that secretions of these
peptides from the fetus increase in parallel with fetal growth
and in response to stressors such as hypoxia. Since hormones
may leak out from the fetoplacental unit because of low-
molecular weight, they are capable of exerting their eﬀects
on the mother. Therefore, the existence of a placental barrier
against these hormones and/or maternal blood is essential
for the homeostasis of pregnancy. The fetoplacental unit is
a rapidly growing organ and allows for maternal exposure
to fetal hormones by retroplacental maternal blood supply
with advancing pregnancy. Thus, fetal peptide hormones
are potentially active not only within the fetoplacental
unit but also on the maternal side during normal and
pathophysiological pregnancy.
Our basic and clinical research has shown that the
placental and maternal barriers to the hormonal eﬀects
of these fetal peptides are the aminopeptidases: placental
leucine aminopeptidase (P-LAP) (EC3.4.11.3) that acts on
oxytocin (OT), vasopressin (AVP) [5–7], and aminopepti-
dase A (APA ) (EC3.4.11.7) that act on AngII, respectively,
[8, 9] as presented in Figure 1. Our research has shown
that placental aminopeptidases are likely involved in both
the onset of labor (preterm labor) and preeclampsia via
degrading fetoplacental peptides [10].2 Journal of Biomedicine and Biotechnology
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Figure 1: Eﬀects of APA deﬁciency on SBP. Systolic blood pressure
(SBP)ofAPA−/−,AP A +/−,andAPA+/+ miceat3months(n = 9to15
per group) was determined by a tail-cuﬀ system. Each datum point
represents the mean measurement of 2-d taken after 4-d training
period. The average ± SEM of each group is represented by an open
circle and a bar. ∗P<. 05.
This paper begins with a description of adverse reactions
that accompany the presently used drugs for preeclampsia
(hypertensive disorder in pregnancy) and preterm labor. We
also discuss the roles of angiotensinase and oxytocinase in
pregnancy and the clinical application of both enzymes. This
is followed by a description concerning the importance of
the knockout mouse ofP-LAPand APA in the understanding
of the active roles of both enzymes in vivo. We then discuss
the roles of P-LAP and APA as promising agents to treat
preeclampsia and preterm labor by degrading bioactive hor-
mones derived from fetoplacental circulation. In addition,
our animal experiments have shown that APA is an excellent
candidate as an antihypertensive agent in humans.
2. AdverseDrugReactions
Preeclampsia and preterm delivery represent serious com-
plications during pregnancy. Preeclampsia is a hypertensive
disorder that occurs during human pregnancy and presents
potentially life-threatening consequences for both mother
and fetus [11]. It is deﬁned as a sustained elevation in blood
pressure (BP; >140/90mmHg, at two readings separated
by 6 hours) accompanied by proteinuria (>300mg/l) in a
previously normotensive woman. Preeclampsia is estimated
to be present in 5–7% of pregnancies in developed countries
and occurs at an even a higher rate in developing countries.
At present, the only cure for preeclampsia eclampsia is
termination of pregnancy, thus obstetricians are forced to
decide upon premature delivery irrespective of gestational
week [12]. According to the March of Dimes Organization
(New York, USA), worldwide approximately one million
deaths occurred during the ﬁrst month of life due to preterm
birth in 2005 [13].
The causes of both preeclampsia and preterm labor
remain unknown, thus present treatments are essentially
symptomatic. Conventional antihypertensive medications
are not routinely administered to preeclampsia patients
since these agents fail to reduce the risk of eclampsia
[12]. Beta2 stimulants and magnesium sulfate are used
to treat preterm labor; however, both drugs cross the
placental barrier and exert their eﬀects on the fetus. In
addition, treatment with Beta2 stimulants presents serious
maternal side eﬀects such as arrhythmia, cardiac ischemia,
and pulmonary edema, with an increased likelihood of
tachycardia in both mother and fetus. Myocardial necrosis
in newborns treated with terbutaline has been reported
[14]. Cardiovascular deterioration due to long-term Beta2-
stimulant therapy contributes to the downregulation of fetal
beta receptors, thus resulting in impaired cardiac function
followingbirth[15].Magnesiumsulfateisessentiallyananti-
convulsant, therefore its administration causes little change
in BP. Undesirable side eﬀects such as depressed respiration
and cardiac arrest frequently occur with increased serum
magnesium levels, and this treatment has been associated
with increased perinatal mortality among fetuses [16].
Recently, we have found that the administration of
preeclampsia doses of magnesium sulfate to pregnant
spontaneously hypertensive rats (SHR) was associated with
delayed cardiovascular vessel formation, suggesting adverse
eﬀects on the fetal heart [17]. It is known that idiopathic
dilated cardiomyopathy in children results in a high rate
of mortality. Cardiac transplantation is the treatment of
choice in those patients who fail to respond to therapeutics
[18]. Although various factors have been suggested to
cause such myocardial damage, no speciﬁc etiology has
been identiﬁed. Injury to myocardial cells is the initiating
factor that leads to cell death. It is likely that in utero
exposure to both Beta2 stimulants and magnesium sulfate
results in considerable fetal myocardium cell loss. The
consequence of this condition is a neonatal myocardium
that fails to generate suﬃcient contractile force to produce
adequate cardiac output. Thus, the fetal eﬀects associated
with these agents are very problematic regarding long-
term prognosis following birth. Given the ever-increasing
worldwide incidences of preeclampsia and preterm labor, it
is imperative that new agents be developed to safely prolong
gestation.
3. Possible Role of Angiotensinase
Because AVP and AngII are known to play an important
role in normal and aberrant (preeclampsia) fetoplacental
circulation, the clearance of these peptides in the placenta
is important for both fetus and mother [19]. The levels of
AngII in umbilical venous blood was found to be higher
than those in umbilical arterial blood in normal pregnancy
and preeclampsia, and the levels in both umbilical and
maternal venous blood in cases of severe preeclampsia
were also much higher than those measured during normalJournal of Biomedicine and Biotechnology 3
pregnancy. The gradient of AngII between umbilical venous
and arterial blood suggests the active involvement of pla-
cental angiotensin-converting enzyme (ACE) (EC 3.4.15.1)
in AngII production in the fetoplacental unit. In addition,
data from Broughton-Pipkin and Symonds [1] showed a
greater diﬀerence between venous and arterial blood in
cases of preeclampsia, which suggested an increased AngII
release from the stressed or transiently hypoxemic fetus
and a decreased degradation by AngII degrading enzyme
(angiotensinase)inplacenta[8].Kingdomandcolleagues[2]
investigated the relation between umbilical arterial oxygen
partial pressure and AngII levels in the umbilical vein during
human delivery. They found that if the human fetus suﬀered
from a low oxygen level caused by stress, the level of AngII in
the umbilical vein was high. This indicates that under stress
conditions, the AngII level will go up in the human fetus. We
found ACE (kininase II) present in the human placenta [20,
21] and showed that maternal serum ACE activity did not
change in preeclampsia compared with normal pregnancy
[19].
The renin-angiotensin system (RAS) is recognized as
an important contributor to hypertension [22], and the
majority of research concerned with this system has focused
onthesynthesisofAngIIanditsinteractionwithangiotensin
receptors [23]. Until recently, little attention had been paid
to AngII degradation and its relevance as a controlling
factor in hypertension [9, 24, 25]. An understanding of the
role of APA in the RAS is important given its ability to
cleave the N-terminal aspartic acid of AngII, thus forming
angiotensinIII(AngIII)andactingasarate-limitingfactorin
the availability of the potent vasoconstrictor, AngII [26]. The
potency of AngIII as a hypertensive agent is approximately
25% that of AngII making AngII the more important ligand;
hence, APA has also been called angiotensinase. Because
AngII concentrations in the enormously enlarging local
tissue (fetoplacental unit) are determined not only by its
synthesisbutalsobyitsdegradation,therateofAPA-induced
degradation of AngII is an important factor as an underlying
mechanism of both fetoplacental and maternal BP [19].
4.PossibleRoleofOxytocinase(Vasopressinase)
The pathophysiology of preterm labor is unknown. This
is not surprising since the mechanisms of onset of labor
at term remain unknown. Although many disorders such
as infections and multiple gestations are associated with
preterm labor, the cause of preterm labor in more than 50%
of pregnancy is idiopathic (spontaneous preterm labor). It
is known that only idiopathic forms of preterm labor are
spontaneous [27]. Spontaneous preterm labor after week 32
is less likely to be complicated by infection [28].
Although the onset of labor is the expression of a
constellation of interrelated events, including fetal control,
steroid hormone changes, prostaglandin production, and
oxytocin action, Liggins et al. [29] have shown that the fetus
signals the onset of labor to the mother. They showed that
the maturation of the fetal hypothalamic-pituitary-adrenal
axis appears to create the signal for a train of events that
result in delivery. They suggested that elevated levels of fetal
cortisol act on the placenta to cause changes in estrogen
and progesterone balance; an increase of estrogen and a
decrease of progesterone and then these changes in steroid
hormones preceding parturition result in the release of large
concentrations of prostaglandin F2 alpha from the maternal
placenta (decidua) in the ovine parturition [30].
On the other hand, Chard and colleagues [4]s u g g e s t e d
the possible involvement of fetal OT during delivery. They
showed that OT and AVP are consistently found in human
umbilical arterial and venous plasma at the time of delivery.
These levels are higher in the umbilical artery than the
umbilicalvein,clearlyindicatingthatthehormonesoriginate
from the fetal pituitary. Oosterbaan and Swaab [3] also
showed that while a rise in amniotic OT levels seems to
reﬂect normal development of the human fetus, increased
amniotic AVP levels may indicate fetal acidosis. Based on
current knowledge, these processes are receptor mediated,
with a central role being ascribed to the activation of the
OT/AVP and their receptor systems, particularly with regard
to uterine contractions as well as decidual activation [31].
It is perplexing that pregnancy continues until term despite
increased fetal OT and OT receptors in human myometrium
and deciduas [32]. Human pregnancy serum and placenta
are known to degrade OT, which should be involved in
regulating OT action. OT has a cystine ring structure at
its N-terminus that is essential for exerting its uterotonic
activity. Until now three proteases have been identiﬁed
concerning the degradation of OT/AVP. These include P-
LAP, postproline cleaving enzyme (EC3.4.21.16) and neutral
endopeptidase (EC 3.4. 24.11) [33].
Although P-LAP degrades, the ring structure of OT at
the peptide bond between Cys1 and Tyr2 and hydrolyzes
the remaining bonds stepwise from the amino terminal.
The other two proteases are not involved in opening the
ring structure of OT [6, 34]. Thus, only P-LAP should be
regardedasoxytocinase.P-LAPispredominantlysynthesized
in placental syncytiotrophoblasts and increases in maternal
blood with advancing pregnancy [35–39].
The change of balance between fetal OT/AVP and P-LAP
duetofetalgrowth,andinresponsetovariousstimulisuchas
hypoxiainfetoplacentalunit,likelytriggerstheonsetoflabor
including preterm labor. Indeed, OT receptor antagonists are
eﬀective in inducing uterine quiescence in various animals
including humans at term [40]. OT receptor antagonists
have been reported to be more eﬀective in the treatment
of preterm labor than beta-agonists [41]. The degradation
of these peptide hormones by P-LAP in the placenta is
necessary in order to maintain homeostasis for both fetus
and mother. While placental aminopeptidases regulate fetal
bioactive peptides in the fetoplacental unit, they work also as
a barrier of bioactive peptides between fetus and mother.
5.Placental AminopeptidaseChanges
Maternal serum APA and P-LAP activities in early mild
preeclampsia patients are higher than those seen in normal
pregnancy patients [42, 43]. As the severity of preeclampsia4 Journal of Biomedicine and Biotechnology
progresses, both APA and P-LAP enzyme activity decrease,
ultimately becoming lower than that measured during
normal pregnancy [42, 44]. It is likely that increased APA
and P-LAP activity in maternal sera before, and immediately
after, the appearance of preeclampsia is in response to the
increased production of AngII/AVP from the fetus.
An understanding of the mechanisms underlying salt-
induced hypertension in the Dahl salt-sensitive rat (DSS) is
of considerable interest given the important role of sodium
in hypertensive disorders [45]. Our laboratory has measured
changes in renal APA activity and histological changes in
the glomerulus of both DSS and Dahl salt-resistant (DSR)
rats [46]. When low- (0.3%) or high- (8%-) salt diets were
administered to DSR and DSS rats, only high-salt DSS
rats revealed systolic blood pressure increases that reached
approximately 150mmHg by week 10, peaking at just under
250mmHg by week 18. Several mechanisms have been
suggested to underlie this response by DSS rats including
sympathetic arousal, deﬁciency in nitric oxide, increased
plasma endothelin-1, and an overactive RAS [46]. Although
there is no evidence that the peripheral RAS is activated,
the local renal RAS is stimulated in DSS rats suggesting
a signiﬁcant contribution by the RAS to the hypertension
seen in this model [45]. Renal APA activity is elevated 3-
fold at week 10 in high-salt DSR rats, similar to that seen
in high-salt DSS rats. Thereafter, it remained at this level.
This increase in renal APA may serve to metabolize AngII,
thus protecting the high-salt DSR rat from hypertension in
response to high salt intake. Although APA activity in high-
salt DSS rats increased 3-fold by week 10, it subsequently
fell back and assumed the level of week 6, by week 18.
T h i si n c r e a s ei nr e n a lA P Aa tw e e k1 0m a ys e r v et od e g r a d e
AngII and temporarily protect this model. However, AngII
levels in high-salt DSS rats at week 10 did not change
despite increased APA activity. Since it is known that a high-
salt diet increases intrarenal angiotensinogen levels in DSS
rats, elevations in AngII levels would be anticipated [45].
Presumably these increases in AngII exceed the degradative
capacity of APA and hypertension results. Changes seen in
human maternal serum APA activity during preeclampsia
are similar to changes measured in renal APA in the DSS rat
model.
If the enzyme levels of maternal serum reﬂect the
production rate in the placenta, then the decreased serum
enzyme levels noted during severe preeclampsia may signify
placental damage due to AngII/AVP-induced vasoconstric-
tion.Thus,thetrophoblasticdegenerationseenduringsevere
preeclampsia may be due to a failure to synthesize APA
and P-LAP. We assayed P-LAP activity once at admission
due to preterm labor (around week 31), at which time all
patientswereevidencingregularuterinecontractionsat<15-
min intervals [47]. Although the speciﬁcity of P-LAP test
is high (97%), its sensitivity is low (29%) for predicting
the prognosis of preterm labor. High speciﬁcity of this test
suggests a direct role of OT/P-LAP system in preterm labor.
Serial assays of P-LAP could be useful as a rough guide for
predicting the onset of labor, since the leveling oﬀ in P-LAP
activity at 11 days prior to the onset of labor may be a useful
marker for the ﬁnal stage of gestation [48]. At term, increases
infetalOToverwhelmP-LAP,resultingincontractionsofthe
uterus triggering the onset of labor. A similar process may
also occur during preterm labor. During normal pregnancy,
suﬃcient levels of P-LAP degrade OT and AVP, and APA
deactivates AngII, thus protecting the mother. However,
a drop in the activity of both enzymes permits elevated
levels of vasoactive peptide hormones from the fetoplacental
circulation to leak into the maternal circulation resulting
in vasoconstriction (hypertension) and uterine contraction
(onset of labor and preterm labor).
6. APA-Deﬁcient (KO) Mouse
While pregnancy in humans and animals is normally
characterized by a relative refractoriness to the hypertensive
response associated with exogenously infused AngII, AngII
sensitivity in the preeclampsia patient becomes higher reach-
ing a level equivalent to, or greater than, that of nonpregnant
women [49]. This phenomenon has been extensively studied
asamostprobablecauseofpreeclampsia;however,itremains
controversial. The use of APA KO mice solved this question.
APAKOmicearehypersensitivetoexogenouslyadministered
AngII, strongly suggesting the involvement of APA in this
AngII sensitivity [50].
Studies employing mice in which genes involved in
angiotensin generation and encoding AngII receptors have
been disrupted have provided information about the func-
tions of these genes. Mice deﬁcient in renin, angiotensino-
gen, ACE, and the type 1 angiotensin receptor (AT1) showed
reduced BP, while APA KO mice evidenced a modest
hypertension. The baseline systolic BP (SBP) is signiﬁcantly
elevatedinAPA−/−)micecomparedwithAPA+/− andAPA+/+
mice(3-month-old).ThecDNAcloningoftheBlymphocyte
diﬀerentiation antigen, BP-1/6C3, identiﬁed BP-1/6C3 as
APA and characterized the APA gene. After the production
of BP-1/6C3/APA-deﬁcient mice, little involvement of APA
in immune system was shown [50]. Although the pathway
of AngII metabolism in humans is still disputed, our
investigations using APA knockout mice have shown that
other enzymes possessing the ability to metabolize AngII
in vitro, including neutral endopeptidase (EC3.4.24.11)
[51], postproline cleaving enzyme (EC3.4.21.26) [52], and
the recently described angiotensin-converting enzyme 2
(ACE2) [53], cannot compensate for the loss of APA [50].
Although the cleavage of C-terminal phenylalanine from
AngII by ACE2 and postproline cleaving enzyme to generate
a vasodilator Ang1-7 is able to inﬂuence BP and AngII
concentrations, ACE2 does not counteract the hypertension
duetoAPAdeﬁciency.Therefore,APAistheessentialenzyme
with respect to RAS mediation hypertension.
When AngII was intraperitoneally infused over a period
of four days (750μg/kg/day) in APA KO mice, SPB increased.
It is evident that the magnitude of BP elevation is greater in
APA−/− mice than in wild-type mice (Figure 2). Following
cessation of AngII infusion SBP dropped over the ﬁrst
day and then decreased to preinfusion levels. In contrast,
SBP remained unchanged in control APA+/+ and APA−/−
mice infused with saline. A deﬁciency in APA would beJournal of Biomedicine and Biotechnology 5
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Figure 2: Eﬀects of chronic AngII infusion on SBP. Daily changes
of SBP in saline infusion [APA−/− () and APA+/+ ()] and AngII
infusion [APA−/− (◦) and APA+/+ (•)] mice. The implantation of
osmotic minipupms was done on day 0. Values are mean ± SEM.
expected to increase the relative concentrations of AngII
by protecting this peptide from degradation. Thus, the
enhanced response to AngII infusion in APA-deﬁcient mice
is consistent with the biochemical property of APA in
metabolizing AngII.
We measured SBP in the APA−/− and APA+/+ mice
ranging from 8 to 60 wk. SBP increased with advancing
weeks (aging) in both the APA−/− and APA+/+ mice. SBP
in the APA−/− was higher than that in APA+/+ mice,
suggesting the possible involvement of APA in the hyper-
tension associated with aging in humans. There is no
developmental and histological diﬀerence in kidneys, heart,
aorta, and brain between APA−/− and APA+/+ mice at 12–
15 versus 49–60 weeks of age. APA KO mice did not show
any developmental and histological abnormality in these
organs.AlthoughincreasedcirculatinglevelsofAngIIinAPA
KO mice result in hypertension, it may not stimulate the
synthesis of growth factor-β, which is capable of producing
morphological changes such as arterial wall hypertrophy and
cardiac abnormality. Since morphological changes in kidney
were not seen in APA KO mice, we compared changes in
urine volume and osmolality between APA−/− and APA+/+
mice.Althoughnotstatisticallydiﬀerent,therewereincreases
measured in APA KO mice, suggesting normal glomerular
functioning.
7. P-LAP-Deﬁcient (KO) Mouse
Oxytocin is the strongest uterotonic substance known and
has been used widely to induce labor. However, success
depends on treatment at the appropriate stage of pregnancy
(justbeforetheonsetoflabor).Inanycase,theuterusismore
sensitive to OT as pregnancy progresses, to the point that
laborreadinesscanbeassessedbytheamountofOTrequired
to cause a contraction. The physiological importance of OT
in modulating the initiation and progression of labor is still
in dispute, since the regulating factor of OT sensitivity is
unknown. Genetic analyses of putative mediators of labor
in the mouse have provided insight into the molecular
cascade that culminates in parturition. Although the initial
characterization of the OT KO mice suggested that OT is not
important in this species [54, 55], subsequent investigations
have shown that OT is important for the precise timing
of the onset of labor. Studies in KO mice also conﬁrm
importantinterrelationshipsbetweenOTandprostaglandins
(PGs) [54]. Previous studies using OT KO mice have shown
that the prepartum interrelationship among OT, PG, and
progesterone important for the precise timing of the onset
of labor is around day 18.
Previously, we cloned the cDNA encoding human P-
LAP from the human placental cDNA library [56]. The
major protein in insulin-responsive glucose transporter
isotype GLUT4 vesicle in rat adipocytes was found to have
aminopeptidase activity. The rat homologue of human P-
LAP is insulin-regulated aminopeptidase (IRAP) [57]. This
protein was independently cloned at about the same time as
P-LAP. Keller et al. reported that the P-LAP/IRAP KO mice
do not have any diﬃculty in maintaining pregnancies and do
not deliver their pups prematurely [58]. We have shown that
P-LAP KO pregnant mice are hypersensitive to exogenously
administered OT, and they deliver their pups prematurely,
showing the possible involvement of P-LAP in this OT
sensitivity during pregnancy. Since WT mice receiving OT
(by implantation of osmotic minipumps) at rates of less than
1U/day showed the onset of labor at the expected time, we
compared the eﬀects of OT at infusion rates of 0 (vehicle
only) and 1.0U/day, which were administered continuously
from day 15.5 in WT and P-LAP KO mice, on the pregnant
term. A signiﬁcant shortening of term was observed in P-
L A PK Om i c e( o n s e to fl a b o r ,3 .3 ± 0.5d a y sa f t e rp u m p
placement) in comparison with WT mice (onset of labor,
4.3±0.3daysafterpumpplacement)withoutadministration
of OT (vehicle only, P<. 05, Figure 2), indicating that P-
LAPKOpregnantmicedelivertheirpupsprematurely.When
mice received 1.0U/day OT, the diﬀerence of onset of labor
between WT and P-LAP KO mice was more evident. P-
LAP KO mice resulted in premature delivery (onset of labor
2.3 ± 0.9 days after pump placement with 1.0U/day OT) in
comparison with WT mice (onset of labor 4.5±0.4d a y sa f t e r
pump placement with 1.0U/day OT, P<. 05) (Figure 3(a)).
There were signiﬁcant diﬀerences concerning duration of
pregnancy comparing with and without administration of
O Ti nP - L A PK Om i c e( P<. 05).
We have shown that AVP is hydrolyzed by P-LAP at
least 3 times more quickly than OT when monitored via
the release of the Tyr residue [7]. Recently, Wallis et al.
[59] have shown that AVP is a physiological substrate for P-
LAP using P-LAP KO mice in vitro. With the administration
of 1.0U AVP intramuscularly in P-LAP KO and WT mice,
there was a statistically signiﬁcant decrease in both urine
volume and water intake/day in both groups. We observed
a statistically signiﬁcant diﬀerence in urine volume between
P - L A PK Oa n dW Tm i c e .K Om i c eo nb o t hP - L A Pa n dA P A
showed that OT and AngII sensitivity is regulated by both
aminopeptidases.6 Journal of Biomedicine and Biotechnology
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Figure 3: (a) Eﬀect of OT infusion on the pregnant time in both WT and P-LAP KO mice. Values are expressed as means ± SD. ∗P<. 05;
WT mice versus P-LAP KO mice in vehicle only, #P<. 05; WT mice versus P-LAP KO mice in 1U/day OT, †P<. 05; P-LAP KO mice in
vehicle versus P-LAP KO mice in 1U/day OT. (b) Eﬀect of recombinant P-LAP on the pregnant time in WT mice. Values are expressed as
means ± SD. ∗P<. 05; vehicle only versus 0.01U/day P-LAP.
8.AP AA ctsasanA ntih ype rt e nsi v eA g e nt
TheSHRiswidelyusedincardiovascularresearchasamodel
of human hypertension, and it oﬀers the opportunity to
understand the mechanisms underlying this disease state. BP
can be normalized in SHRs with angiotensin receptor block-
ers (ARBs) and ACE inhibitors, suggesting the involvement
of the RAS. Although SHRs do not evidence elevated renin
activity or increased plasma AngII concentrations relative to
their normotensive counterpart Wistar-Kyoto (WKY) rats,
they do possess a supersensitivity to AngII [60]. These
results suggest that the SHR is more responsive to the
vasoconstrictive eﬀects of AngII than WKY rats. Since we
have shown that the administration of a mixture of APA
and aminopeptidase N (APN) (EC 3.4.11.2) puriﬁed from
human placenta reduces BP in SHRs, we have tested the
eﬀect of recombinant APA on BP in SHRs [61]. We found
that bolus intravenous injections of recombinant APA at
various doses signiﬁcantly decreased systolic BP in SHRs
at the 3-hour time point. Among them, the 0.016mg/kg
dose of APA caused a gradual decrease in systolic BP,
reaching approximately −4 0 m m H gb y2 4 h .M u c hh i g h e r
doses of APA revealed a sharp decline of BP (approximately
50mmHg at 3h); however, they showed the reversal of its
antihypertensive eﬀect after 3h [60].
Song and Healy [62] have reported that APA levels in
glomeruli increased with the infusion of a subpressor dose of
AngII in normotensive rats. They also showed that treatment
with an ACE inhibitor reduced kidney APA activity in SHRs,
suggesting that APA expression may be positively coupled
with AngII levels.
Our laboratory has also shown that APA activity
increased with the addition of AngII to a primary culture
of normal placental trophoblasts [63]. We determined that
AngII stimulated the proliferation of trophoblastic cells
via the AT1 receptor subtype linked to protein kinase
C/MAPK-dependent signaling pathways [64]. APA activity
was upregulated during AngII-induced cell proliferation;
thus, it appears that increased levels of either AngII or APA
result in a compensatory response, presumably representing
an attempt to maintain homeostasis. This may explain why
the highest dose of APA resulted in the greatest reversal of
the antihypertensive eﬀect. The lower doses of APA may be
below the threshold to induce compensatory increases in
circulating AngII.
Because the glutamic acid residue in the GAMEN
motif is important for the enzymatic action of the
M1aminopeptidase family [65], we replaced Glu360 with a
glutamine residue (APA E360Q). As expected, APA E360Q
did not show any hydrolytic activity against the ﬂuorogenic
synthetic substrate Glu-MCA or AngII (data not shown).
APA E360Q (no APA enzymatic activity) did not show any
eﬀect on SBP of SHRs. The 0.016mg/kg dose of APA failed
to inﬂuence SBP except for a slight, but nonsigniﬁcant,
decline at 48 hours in Wistar-Kyoto (WKY) rats. Although
a number of pathogenic factors have been proposed to
underlie the hypertension of SHRs [66], the present results
suggest an important role for APA-mediated degradation of
AngII. We have shown that renal APA is involved in the
development of hypertension and the regulation of BP in
SHRs [67].
We compared the antihypertensive eﬀects of daily bolus
injections of APA (0.016mg/kg) against continuous infusion
of the ARB candesartan (0.1mg/kg/day) over 5 days in
SHRs. The magnitude of the antihypertensive eﬀect by APA
and candesartan was similar: APA, 175.8 ± 13.5mmHg to
147.6 ± 16.3mmHg at 24h; ARB, 169.5 ± 10.3mmHg to
137.4 ± 11.0mmHg at 24h (Figure 4). The antihypertensiveJournal of Biomedicine and Biotechnology 7
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Figure 4: Comparison of APA (0.016mg/kg) and candesartan on
BP in SHRs. Intravenous injection of recombinant APA (n = 5) and
candesartan (n = 5) signiﬁcantly decreased SBP for 5d in SHRs.
ThemagnitudeoftheantihypertensiveeﬀectsofAPA(0.016mg/kg)
and ARB (0.1mg/kg) was similar. APA (0.016mg/kg): bolus
injection every day for 5d; candesartan (0.1mg/kg): continuous
infusion by osmotic minipumps for 5d. ∗P<. 05, ∗∗P<. 01
compared with pretreatment period.
eﬀects induced by a bolus injection of APA (0.016mg/kg)
are similar to those obtained with continuous drop infusion
of nitroprusside (0.5–5mg/kg/min) in humans [68]. Other
laboratories have reported that intravenous administration
of the ARB Dup753 (10mg/kg) decreased blood pressure in
SHRs for at least 24 hours, and intravenous injection of the
ACE inhibitor captopril (2mg/kg) reduced blood pressure
in SHRs for 3 hours [60]. Although the diﬀering delivery
methods make comparison of the present results somewhat
diﬃcult, it does appear that the application of a low dose
of APA was equivalent to an ARB and ACE inhibitor with
respecttoantihypertensiveeﬃcacy.TheeﬀectivedoseofAPA
inthepresentstudywasaboutone-tenththatofcandesartan.
Thus, in a comparison of a bolus injection of APA (MW
109kDa) and a continuous infusion of candesartan (MW
440kDa) for 36 hours, APA possesses a 2300-fold advantage
in eﬃcacy over candesartan. Our data suggest that AngII
degradation in blood is a much more eﬀective approach
than blocking AngII receptor binding in treating imminent
hypertension as resulting from hypertensive encephalopathy,
apoplexy, and acute heart failure, and acute dissection of
aorta.
9. APA is an AntihypertensiveDrug
CandidateinPregnancy
It is known that the administration of ACE inhibitors causes
hypotension which can be lethal to the human fetus. This
suggests an important role for AngII in the fetoplacental
circulation [69]. Taken together, these ﬁndings present a
treatment dilemma since the increased synthesis of AngII
by the fetus signiﬁcantly contributes to preeclampsia; while
vasoconstriction of the fetoplacental circulation may be of
primary importance in preeclampsia [70]. However, the
administration of conventional antihypertensive agents to
the mother is detrimental to the fetus.
Two animal models of preeclampsia have been reported.
Davisson and colleagues [71]n o t e das p o n t a n e o u sm o u s e
syndrome that approximates preeclampsia. These investiga-
tors placed thoracic aortic telemeters in nonpregnant female
BPH/5 and C57BL/6 mice. Following recovery from surgery,
ﬁve days of baseline mean arterial pressure (MAP) record-
ings were taken. Next, strain-matched timed pregnancies
were initiated. Prior to pregnancy, members of each strain
indicated comparable total urinary protein levels; however,
the BPH/5 mice evidenced an elevated MAP compared with
the C57BL/6 mice. Although blood pressures were stable
during the initial two weeks of pregnancy in members of
both strains, at the beginning of the last trimester MAP
became elevated in the BPH/5 mice peaking just prior to
delivery and then returned to baseline following delivery.
There was also evidence of late gestational proteinuria
and progressive glomerulosclerosis. No such changes were
measured in members of the C57BL/6 strain. Further, the
BPH/5 mice produced smaller litter sizes even though
the number of fetuses was comparable to C57BL/6 mice
earlier in gestation. A second preeclampsia animal model
was developed by Maynard et al. [72]. These investigators
observed increases in placental soluble fms-like tyrosine
kinase 1 (sFlt1) in preeclampsia patients accompanied by
decreases in circulating VEGF, and placental growth factor
(PlGF). The administration of VEGF and PlGF corrected
the resulting endothelial dysfunction and suggested the
following experiment. Pregnant rats were administered
sFlt1, a VEGF, and PlGF antagonist, which prompted the
development of proteinuria and glomerular endotheliosis,
both characteristic of preeclampsia. The authors concluded
that elevated and excessive levels of circulating sFlt1 are
a major contributor to the pathogenesis of preeclamp-
sia.
Since the diagnosis of preeclampsia is determined essen-
tially by increased BP, we used pregnant SHRs as a model
of preeclampsia. Bestatin is a low-molecular-weight peptide
that inhibits APA and APN. Previously, we showed that
the administration of bestatin to pregnant rats results in
f e t o p l a c e n t a lg r o w t hr e s t r i c t i o n[ 73]. We have also found
that bestatin administration in pregnant rats results in the
disappearance of BP decline during late gestation, which is
commonlyobservedinbothSHRandWKYpregnantrats.In
addition, bestatin administration to pregnant rats resulted in
increased proteinuria [70].
We have tested the eﬀects of APA and ARB on hyperten-
sion in pregnant SHRs. Bolus injections of APA and ARB
were administered via osmotic minipumps. The doses were
as follows: recombinant APA (0.016–0.16mg/kg/day) (n =
5) and ARB(candesartan:CV-11974, Takeda Pharmaceutical
Co. Ltd, Osaka, Japan; 0.1–1mg/kg/day) (n = 5). Initial
doses of ARB were titrated to match those used for human
hypertension. Bolus doses of each drug injected were dou-
bled daily up to 10-fold until the end of drug treatment from
day 10 to day 20. Since mean BP diﬀered across groups,8 Journal of Biomedicine and Biotechnology
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Figure 5: Changes of SBP during mid- and late-term pregnancy in
SHRswithandwithoutadministrationofAPAandcandesartanand
WKYs without administration of any drugs. SHR (control, n = 5),
SHR (APA: 0.016–0.16mg/kg/day, n = 5), SHR (candesartan: 0.1–
1mg/kg/day ,n = 5), and WKYs (control, n = 5).
the changes in BP following administration of drugs were
compared with baseline BP measured prior to the initiation
of the experiment. Figure 5 shows the changes in systolic BP
during mid and late pregnancy (from day 10 to day 20) in
SHRs with administration of candesartan and APA. Changes
in systolic BP during mid and late pregnancy in pregnant
WKYs without administration of any drugs (control) are
also shown. The magnitude of antihypertensive eﬀects of
APA and candesartan was very similar (−30mmHg) at day
20. There were no diﬀerences in fetal and placental weights
comparing control SHRs and drug-administered groups.
Fetal and placental weights in SHRs were signiﬁcantly lower
than those of WKY rats. These results are consistent with
our previous data and the data of others. There were no
diﬀerences in fetal kidney and heart weights between drug-
administrated groups and the control. Although there were
many mature renal glomeruli, which contain red blood
corpuscles, in members of the APA and control groups, few
were found in members of the ARB group.
It is known that both ACE inhibitor and ARB therapy in
the second and third trimesters of pregnancy have been asso-
ciatedinhumanswithfetalrenaldamage,oligohydroamnios,
anhydroamnios, and even fetal death [74]. Recently, Bowen
and colleagues [75] have reported the increased frequency
of pregnant women with ACE inhibitor exposure. Since
both block AngII action via degradation and binding of
AngII, respectively, the antihypertensive eﬀect results from
a loss of AngII stimulation in pregnant SHRs. The antihy-
pertensive eﬀects of APA and candesartan were maintained
by increasing the dose with advancing gestation, suggesting
that AngII synthesis increases over time in pregnant SHRs.
This likely represents increased leakage of AngII from the
fetoplacental unit into maternal circulation with advancing
gestation. Our study suggests an important role for APA-
mediated degradation of AngII in hypertension in pregnant
SHRs. Since APA is a large molecule that does not cross the
placenta, APA may be a useful drug for the treatment of
preeclampsia.
10. P-LAP as a Possible Agent for
Treatment of Preterm Delivery
We administered recombinant P-LAP continuously from day
15.5 in WT mice (Figure 3(b)). Signiﬁcant elongation in
the onset of labor was observed in WT mice in response
to P-LAP infused at 0.01U/day (onset of labor 5.7 ± 0.7
days after pump placement with 0.01U/day P-LAP versus
4.4 ± 0.3 days for vehicle infused, P<. 05). Results from
this preliminary investigation concerning the administration
of recombinant P-LAP at 0.1U/day continuously from day
15.5 in WT mice indicated elongation of the onset of labor
without any negative eﬀects on mother and pups (data not
shown). We used this same daily dose of recombinant P-LAP
(0.01U/day) in a subsequent experiment. Both parturition
time and number of viable pups in the P-LAP-treated
group were not signiﬁcantly diﬀerent from those in vehicle
group. Speciﬁcally, the number of pups in the vehicle group
was 5.8 ± 1.3pups/litter, and in the P-LAP group 6.0 ±
1.8pups/litter [76].
As mentioned previously, the prepartum interrelation-
ship among OT, PG, and progesterone important for the
precise timing of the onset of labor is around day 18 in
mouse. The administration of recombinant P-LAP surpassed
these phenomena and thus delayed the onset of labor in
mouse. On the other hand, we [76]a n dI m a m u r ae ta l .[ 77]
have shown that OT at higher doses was able to precipitate
labor, indicating that augmentation of uterine contraction
before normal labor is achievable despite low uterine OTR
levels and elevated plasma progesterone concentrations if the
l e v e lo fO Ti ss u ﬃciently high. Therefore, it is suggested that
the regulation of the onset of labor mainly depends on OT,
and its degradation by P-LAP and is therefore, independent
of both PG and progesterone. Indeed, OT exaggerates the
inherent pattern of uterine motility, which often becomes
clinically evident during the last trimester and increases as
term is approached. Therefore, OT is the most common
method of induction of human labor. OTR antagonists are
eﬀective in inducing uterine quiescence in various animal
species including humans at term. OTR antagonists have
been reported to be eﬀective in the treatment of preterm
labor compared with beta agonists [78]. However, these
agents are small molecules and therefore cross the placenta
and have various pharmacological eﬀects on the fetus [14,
15, 79]. Since P-LAP has a molecular weight of 160–
165kDa, it does not cross the placenta. Thus, P-LAP might
be a useful agent for the treatment of preterm labor in
pregnancy. In addition, P-LAP may be useful in avoiding
the onset of midnight labor, which is troublesome for all
obstetricians. Since P-LAP and APA are large molecules
that do not cross the placental barrier, they represent
promising agents to treat preeclampsia and preterm labor
by degrading bioactive hormones derived from fetoplacental
circulation.Journal of Biomedicine and Biotechnology 9
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Figure 6: Changes of daily SBP in SHRs during middle and
late pregnancy under administration of sex steroids and olive oil
(control). Only E with P administration reduced signiﬁcantly SBP
at late pregnancy compared with those in others (at days 19, 20).
∗P<. 001.
11. FinalComments
The ultimate goal regarding treatment for both preeclampsia
and preterm labor must be maternally directed without
inﬂuencing the fetoplacental unit. We have previously
reported positive eﬀects with estradiol and progesterone
treatment for severe preeclampsia [80]. In 1941, G. V. Smith
a n dO .W .S m i t h[ 81] reported the successful treatment
of severe preeclampsia with estradiol and progesterone.
However, very little attention was paid to this treatment
approach due to the potential teratogenicity of these com-
pounds. Even so at present, it is common to use estradiol
and progesterone in human-assisted reproduction during
the early days of pregnancy. These positive outcomes in
preeclampsia and/or preterm labor are likely via activation of
placentalaminopeptidasesthatdegradevasoactivehormones
thus reducing maternal BP [80]. We have shown that
progesterone, and probably estrogen, increases APA levels
in human trophoblastic cells. We employed the RNase
protection assay method to increase accuracy and sensitivity
in determining APA mRNA levels [82]. Progesterone has
recently been reevaluated as a tocolytic agent. However,
estrogen is not commonly used during pregnancy except to
assistreproduction.Wehaveshownthatexogenouslyadmin-
istered estradiol benzoate at 1μg/day or less in pregnant rats
(days12–19) had no eﬀect on pup survival and fetoplacental
growth. However, at a dose of 10μg/day or more, there
was a tendency toward reduced fetoplacental growth. Thus,
it is important to closely monitor the dosage of estrogen
administered during pregnancy [83].
We have shown the eﬀects of 17β-estradiol benzoate
(E) and 17-α hydroxyprogesterone capronate (P) on BP
and fetoplacental growth in SHRs. E (10μg/day) and P
(2mg/day) were administered intraperitoneally to pregnant
SHRs from day 16 to 19. These steroids had no eﬀect
on the number of pups delivered; however, there were
decreases in birth weights and placenta weights except in
the case of placentae by E accompanied with P. Mean SBP
decreased from days14–16 to days 18–20 of pregnancy in
SHRs. Although E and P had no eﬀect on BP, E accompanied
with P signiﬁcantly decreased BP as compared with control
SHRs at days 19 and 20 of pregnancy (unpublished data).
We also measured APA activity in the maternal renal cortex
in this experiment. Treatment with both E and P showed
a tendency to increase APA activity, but this eﬀect was
not statistically signiﬁcant compared with control (olive
oil). However, APA activity in the kidney was signiﬁcantly
increased by E accompanied with P (Figure 6, unpublished
data).
We continued such treatment in appropriate cases and
found that both mother and newborn remained in good
health. We have followed several severe preeclampsia cases.
One female baby treated with only estradiol and proges-
terone is now 36 years old and has two healthy children,
suggesting no negative eﬀects. This treatment approach
could be used for preeclampsia on an interim basis until,
hopefully, aminopeptidases are approved as drugs for this
purpose.
Barker’s hypothesis [84] suggests that reduced fetal
growth is correlated with the occurrence of a number of
chronic conditions later in life including coronary heart dis-
ease, stroke, diabetes, hypertension, and depression. Given
the ever increasing world-wide incidences of preeclampsia
and preterm labor, it is imperative that new agents be
developed to safely prolong gestation. We believe the use of
aminopeptidases hold promise in this regard.
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